Schizophrenia is a chronic neuropsychiatric disorder affecting an estimated 3.5 million
individuals in the United States. 1 It is characterized by a combination of positive symptoms …

The currently available antipsychotics mostly treat the positive symptoms of schizophrenia
and have at least one adverse effect as a potential liability. Encouraging data suggest …

Antipsychotics remain the current standard of care for mental disorders including
schizophrenia (~ 1% prevalence) and bipolar mania (~ 3% prevalence), and generate over …

The introduction of the first antipsychotic medication in the early 1950s revolutionized mental
health care strategies and led to the era of deinstitutionalization, a period in which patients …

Schizophrenia remains one of the most severe medical diseases. Current dopamine
modulating first-generation and second-generation antipsychotics target mainly positive …

Introduction: Schizophrenia is one of the most serious mental disorders. Its treatment
remains challenging, as existing antipsychotic antidopaminergic medications improve …

Schizophrenia is a chronic psychotic disorder with typical onset in early adulthood and a
lifetime prevalence of approximately 1%. In addition to the hallmark symptoms of psychosis …

Background Schizophrenia is a disabling disorder that profoundly affects functioning and
quality of life. While available antipsychotics have improved outcomes for patients with …

Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a
large percentage of persons with schizophrenia remain at least partially nonresponsive to …

Although enormous progress has been made in the treatment of schizophrenia, and the use
of existing pharmacologic agents can have a dramatic effect on the short-and long-term …